文献库搜索 | GeneLibs

Sabari(J),Stiles(BM) J Surg Oncol 2026-05-00

Early-stage ALK-positive non-small cell lung cancer (NSCLC) represents a distinct molecular subset requiring individuali...

Shi(Y),Li(Z),Chen(R),Shao(C),Zhou(H),Li(X)... J Thorac Dis 2026-02-28

...ALK) in lung adenocarcinoma mouse, including pSTAT3, pAKT, and pERK, which also play an important role in the developmen...

Catueno(S),Frost(M),Cuglievan(B),Gibson(A)... J Pediatr Hematol Oncol 2026-04-01

...ALK-positive ALCL and HLH required intensive care and chemotherapy, experienced multiple relapses, and ultimately achiev...

Zhou(Y),Yi(M),Yan(J),Chen(H),Yang(J) Pharmacology 2026-03-12

...ALK) mutations are key oncogenic drivers in non-small-cell lung cancer (NSCLC). Although ALK tyrosine kinase inhibitors ...

Holic(LJ),Trichy(NS),Braat(J),Olivares(S),... Am J Surg Pathol 2026-06-01

...ALK fusion Spitz neoplasms and provide the largest data set of ALK fusion Spitz with clinical follow-up. In addition to ...

Marrable(L),Asairinachan(A),Farwana(M),Sut... Int J Pediatr Otorhinolaryngol 2026-05-00

...ALK) in four patients. The upfront definitive treatment was open resection in two patients and endoscopic removal in one...

Wali(AF),Talath(S),Babiker(R),El-Tanani(M)... Front Pharmacol None

...ALK pathways drives tumor growth, survival, and metastasis. While synthetic kinase inhibitors have improved outcomes, th...

Niu(Y),Ding(B),Shi(J),Yang(Y),Zhao(J),Wang(D) Cancer Manag Res None

...ALK) rearrangement represents a rare molecular subtype of lung squamous cell carcinoma (LSCC). Although ALK tyrosine kin...

Kwon(I),Sassoon(J),Mori(M),Brandwein-Weber(M) Head Neck Pathol 2026-03-13

ALK positive histiocytosis (APH) is a rare histiocytic neoplasm defined by an ALK fusion and generally characterized by ...

Yahya(TAA),Al-Qadhi(MA) Bioorg Chem 2026-06-15

...ALK) is a clinically validated oncogenic driver in multiple malignancies; however, the long-term efficacy of ALK tyrosin...